Unique Features of Young Age Breast Cancer and Its Management

다국어 초록 (Multilingual Abstract)

Young age breast cancer (YABC) has unique clinical and biologicalfeatures that are not seen in older patients. Breast tumor biologyis more aggressive and is associated with an unfavorableprognosis in younger women. The diagnosis of breast cancer isoften delayed, resulting in their initial presentation with more advanceddisease. Together, these characteristics lead to a poorerprognosis in younger women than in older women. Young womenwho receive breast-conserving therapy have a higher rate oflocal recurrence. Therefore, it is important to secure sufficient resectionmargins and consider boost radiotherapy to prevent localtreatment failure. Based on age alone, patients with YABCshould be regarded as high-risk cases, and they should be treatedwith adjuvant chemotherapy. Special considerations regardingpsychosocial factors and fertility should be taken into accountfor young patients. This review discusses the major considerationsand principles concerning the management of patientswith YABC

참고문헌 (Reference)

1 Aebi S, "chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?" 355 : 1869-1874, 2000

2 Chung M, "Younger women with breast carcinoma have a poorer prognosis than older women" 77 : 97-103, 1996

3 Han W, "Young age:an independent risk factor for disease-free survival in women with operable breast cancer" 4 : 82-, 2004

4 Kim HJ, "Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ERnegative subtype" 130 : 499-505, 2011

5 Anders CK, "Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression" 26 : 3324-3330, 2008

6 Stewart BW, "World Cancer Report 2014" World Health Organization 2014

7 Gonzalez-Angulo AM, "Women age < or = 35 years with primary breast carcinoma: disease features at presentation" 103 : 2466-2472,

8 Colleoni M, "Very young women (<35 years) with operable breast cancer: features of disease at presentation" 13 : 273-279, 2002

9 Fowble BL, "The influence of young age on outcome in early stage breast cancer" 30 : 23-33, 1994

10 Oh JL, "The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is “young”?" 65 : 1345-1352, 2006

11 Jobsen JJ, "The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy" 37 : 1820-1827, 2001

12 Partridge AH, "The effect of age on delay in diagnosis and stage of breast cancer" 17 : 775-782, 2012

13 Beadle BM, "Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach" 73 : 734-744, 2009

14 De Laurentiis M, "Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials" 26 : 44-53, 2008

15 Peto J, "Stratton MR. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer" 91 : 943-949, 1999

16 Colleoni M, "Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease" 17 : 1497-1503, 2006

17 Nixon AJ, "Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer" 12 : 888-894, 1994

18 Han W, "Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer" 119 : 193-200, 2010

19 Mulder RL, "Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation:a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group" 14 : e621-e629, 2013

20 Shak S, "Quantitative gene expression analysis in a large cohort of estrogen receptorpositive breast cancers: characterization of the tumor profiles in younger patients (≤40 yrs) and in older patients (≥70 yrs)" 2010

21 Howard-Anderson J, "Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review" 104 : 386-405, 2012

22 Fourquet A, "Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up" 17 : 719-725, 1989

23 de Sanjosé S, "Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study" 106 : 588-593, 2003

24 Ahn Sei Hyun, "Prevalence of BRCA1 and BRCA2 Mutations in Korean Breast Cancer Patients" 대한의학회 19 (19): 269-274, 2004

25 Anglian Breast Cancer Study Group, "Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases" 83 : 1301-1308, 2000

26 Warner E, "Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer" 91 : 1241-1247, 1999

27 Whittemore AS, "Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer" 60 : 496-504, 1997

28 Arriagada R, "Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer" 13 : 1404-1413, 2002

29 Quan ML, "Postmastectomy radiation and recurrence patterns in breast cancer patients younger than age 35 years: a population-based cohort" 21 : 395-400, 2014

30 Bedrosian I, "Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients" 102 : 401-409, 2010

31 Ahn SH, "Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer Society" 25 : 2360-2368, 2007

32 Moore HC, "Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: an international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance)" 32 : 2014

33 Goldhirsch A, "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013" 24 : 2206-2223, 2013

34 Friedman LC, "Medical and psychosocial predictors of delay in seeking medical consultation for breast symptoms in women in a public sector setting" 29 : 327-334, 2006

35 Zablotska LB, "Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma" 97 : 1404-1411, 2003

36 Davies C, "Longterm effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial" 381 : 805-816, 2013

37 Neuschatz AC, "Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy" 97 : 30-39, 2003

38 Kim J, "Ki-67 level in hormone receptor positive breast cancer patients: a retrospective review of 9,061 Korean women" 31 : 2013

39 Komoike Y, "Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases" 106 : 35-41, 2006

40 Choi DH, "Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray" 11 : 404-411, 2005

41 Del Mastro L, "Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women:systematic review and meta-analysis of randomized trials" 40 : 675-683, 2014

42 Kroenke CH, "Functional impact of breast cancer by age at diagnosis" 22 : 1849-1856, 2004

43 Newman B, "Frequency of breast cancer attributable to BRCA1 in a populationbased series of American women" 279 : 915-921, 1998

44 Malone KE, "Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases" 88 : 1393-1402, 2000

45 Loren AW, "Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update" 31 : 2500-2510, 2013

46 Xiong Q, "Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience" 92 : 2523-2528, 2001

47 Kroman N, "Factors influencing the effect of age on prognosis in breast cancer: population based study" 320 : 474-478, 2000

48 Azim HA Jr, "Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling" 18 : 1341-1351, 2012

49 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials" 365 : 1687-1717, 2005

50 Del Mastro L, "Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial" 306 : 269-276, 2011

51 Kroman N, "Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma" 100 : 688-693, 2004

52 Partridge AH, "Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial" 31 : 2692-2698, 2013

53 Voogd AC, "Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials" 19 : 1688-1697, 2001

54 Barber MD, "Diagnostic delay in breast cancer" 91 : 49-53, 2004

55 Samphao S, "Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging" 198 : 538-543, 2009

56 Minisini AM, "Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era" 20 : 503-507, 2009

57 Jassem J, "Delays in diagnosis and treatment of breast cancer: a multinational analysis" 24 : 761-767, 2014

58 Walker RA, "Breast carcinomas occurring in young women (< 35 years) are different" 74 : 1796-1800, 1996

59 Anders CK, "Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?" 29 : e18-e20, 2011

60 "Breast cancer version 3" National Comprehensive Cancer Network

61 Northouse LL, "Breast cancer in younger women: effects on interpersonal and family relations" (16) : 183-190, 1994

62 Sidoni A, "Breast cancer in young women: clinicopathological features and biological specificity" 12 : 247-250, 2003

63 Winchester DP, "Breast cancer in young women" 76 : 279-287, 1996

64 Zabicki K, "Breast cancer diagnosis in women < or = 40 versus 50 to 60 years:increasing size and stage disparity compared with older women over time" 13 : 1072-1077, 2006

65 American Cancer Society, "Breast Cancer Facts & Figures 2013-2014" American Cancer Society 2013

66 American Cancer Society, "Breast Cancer Facts & Figures 2011-2012" American Cancer Society 2011

67 Robson M, "BRCAassociated breast cancer in young women" 16 : 1642-1649, 1998

68 Robson M, "BRCA-associated breast cancer: absence of a characteristic immunophenotype" 58 : 1839-1842, 1998

69 Ministry of Health and Welfare, "Annual Report of Cancer Statistics in Korea in 2011" Korea Central Cancer Registry 2012

70 Bollet MA, "Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first" 82 : 272-280, 2007

71 Regan MM, "Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials" 22 : 1094-1100, 2013

72 Goldhirsch A, "Adjuvant therapy for very young women with breast cancer: need for tailored treatments" (30) : 44-51, 2001

73 Noh WC, "32 ASTRRA study: a randomised phase III study for evaluating the role of the addition of ovarian function suppression (OFS) to tamoxifen in young women (<45 years) with hormone-sensitive breast cancer who remain in premenopause or regain menstruation after chemotherapy: a Korean Breast Cancer Study Group (KBCSG) trial" 8 : 67-68, 2010